The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The use of lorazepam TID for chronic insomnia
Abstract
Patients with primary insomnia typically complain of daytime fatigue and stress and have been shown to have long latencies on the Multiple Sleep Latency Test and increased whole body metabolism. However, typical treatment strategies for patients with insomnia rarely include any component to deal with these daytime symptoms. In the present study it was hypothesized that a 24-h treatment, lorazepam 0.5 mg TID, would be superior to an evening treatment, lorazepam 1.5 mg HS, in patients with primary insomnia. In a repeated measures crossover design, 12 patients with chronic insomnia received placebo or lorazepam 0.5 mg TID in one 4-night lab stay and placebo or lorazepam 1.5 mg HS in another lab stay. Both doses of medication were effective in improving objective and subjective measures of sleep and in reducing nocturnal whole body metabolic rate. Latencies on daytime nap testing were significantly reduced from a 14-min average to an average of 10 and 12 min, respectively, in the lorazepam 0.5 and 1.5 mg conditions. Significant differences were not found on psychomotor performance. Subjective reports of anxiety and confusion were increased in the morning after receiving lorazepam 0.5 mg in the evening but tension was reduced and subjective alertness was improved in the evening after daytime administration of lorazepam 0.5 mg. It was concluded that measurement and treatment of daytime symptoms is appropriate in patients with chronic insomnia but that rebounds in anxiety near the end of metabolic activity of lorazepam may make it a poor treatment choice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?
Ford, D. E. (1989) · JAMA · doi:10.1001/jama.1989.03430110069030 · Cited by 2,252
24-Hour Metabolic Rate in Insomniacs and Matched Normal Sleepers
Bonnet, M. H., & Arand, D. L. (1995) · Sleep · doi:10.1093/sleep/18.7.581 · Cited by 557
Self-citationLorazepam: Effects on Sleep and Withdrawal Phenomena
Kales, A., Bixler, E. O., Soldatos, C. R., Jacoby, J. A., & Kales, J. D. (2008) · Pharmacology · doi:10.1159/000138160 · Cited by 29
Cited by
Hyperarousal and insomnia: state of the science
Bonnet, M. H., & Arand, D. L. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2009.05.002 · Cited by 914
Self-citationBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
The Clinical Use of the MSLT and MWT
Arand, D., Bonnet, M., Hurwitz, T., Mitler, M., Rosa, R., & Sangal, R. B. (2005) · Sleep · doi:10.1093/sleep/28.1.123 · Cited by 389
Self-citationBonnet, M. H., & Arand, D. L. (1997) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(97)90012-5 · Cited by 363
Self-citationHyperarousal in insomnia disorder: Current evidence and potential mechanisms
Dressle, R. J., & Riemann, D. (2023) · Journal of Sleep Research · doi:10.1111/jsr.13928 · Cited by 218
Metadata
- Authors
- Bonnet, M. H., & Arand, D. L.
- Venue
- International Clinical Psychopharmacology
- Published
- 1999-03
- Volume
- 14
- Issue
- 2
- Pages
- 81-89
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1993124388
- Cited by
- 179
- References
- 3
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of lorazepam TID for chronic insomnia. https://app.cochat.ai/papers/10.1097/00004850-199903000-00004
- The paper
- Bonnet, M. H., & Arand, D. L. (1999). The use of lorazepam TID for chronic insomnia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199903000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.